Durability of Antiplatelet Effect of a Novel Extended-Release Formulation of Acetylsalicylic Acid, Durlaza in CVD (Cardiovascular Disease) Patients at Risk of High Platelet Turnover

Trial Profile

Durability of Antiplatelet Effect of a Novel Extended-Release Formulation of Acetylsalicylic Acid, Durlaza in CVD (Cardiovascular Disease) Patients at Risk of High Platelet Turnover

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Apr 2016

At a glance

  • Drugs Aspirin (Primary)
  • Indications Cardiovascular disorders
  • Focus Pharmacodynamics
  • Acronyms DURATION
  • Sponsors New Haven Pharmaceuticals
  • Most Recent Events

    • 21 Apr 2016 Results presented at the 68th Annual Meeting of the American Academy of Neurology
    • 10 Nov 2015 According to a New Haven Pharmaceuticals media release, results were presented at the American Heart Association's Scientific Sessions event.
    • 10 Nov 2015 Results published in the Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top